CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Saquinavir +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00001040
NCT00001040Phase 2Completed
CompareCT.gov

Double-Blind, Randomized, Phase II Study of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (Dideoxycytidine; ddC) Versus Ro 31-8959 Plus AZT Plus ddC

Hoffmann-La Roche·interventional·Posted Aug 31, 2001·Updated Mar 1, 2011

In Brief

A Phase 2 clinical trial evaluating Saquinavir, Zidovudine, and 1 other intervention for HIV Infections. Completed, across 10 sites.

Detailed Summary

PRIMARY: To determine the efficacy and toxicity of three treatment regimens: saquinavir mesylate (Ro 31-8959) plus zidovudine (AZT) vs. AZT plus zalcitabine (dideoxycytidine; ddC) vs. Ro 31-8959 plus AZT plus ddC. SECONDARY: To investigate the pharmacokinetics and effects on various clinical parameters of the three regimens.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 31, 2001
Primary CompletionMay 1, 1994
TodayJul 2, 2026
Posted 24.8 years ago

Interventions

Saquinavirdrug

Zidovudinedrug

Zalcitabinedrug